The translocator protein (TSPO) has been identified as a positron emission tomography (PET)-visible biomarker of inflammation and promising immunotherapeutic target for the treatment of Alzheimer’s disease (AD). This evidence concerns the gene TSPO and early-onset autosomal dominant Alzheimer disease.